Relative bioavailability of neoral versus sandimmune in the presence of a P450IIIA and P-glycoprotein inhibitor

Transplantation Proceedings

Volumn 30, Issue 5, 1998, Pages 1664-1665

  Choc, M G ^a   Mueller, E A ^b   Robinson, W T ^b   Kumle, A ^b   Smith, H T ^b   Charnick, S B ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450; DRUG METABOLITE; GLYCOPROTEIN P; INHIBITOR PROTEIN;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG FORMULATION; DRUG METABOLISM; DRUG TRANSPORT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CROSS-OVER STUDIES; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOSAGE FORMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METABOLIC CLEARANCE RATE; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; PROTEIN SYNTHESIS INHIBITORS;

EID: 0031657645     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(98)00383-2     Document Type: Conference Paper

References (6)

1. Meinzer A, Mueller EA, Niese D, et al: In Principles of Drug Development in Transplantation and Autoimmunity Lieberman R, Mukherjee A (eds): R.G. Landes Co; 1996, p 259
2. Wu C-Y, Benet LZ, Hebert MF, et al: Clin Pharmacol Ther 58:492, 1995
3. Benet LZ, Wu C-Y, Hebert MF, et al: J Controlled Release 39:139, 1996
4. Kovarik JM, Vernillet L, Mueller EA, et al: Ther Drug Monit 16:519, 1994
5. Reymond J-P, Sucker H, Vonderscher J: Pharm Res 5:677, 1988
6. Tarr BD, Yalkowsky SH: Pharm Res 6:40, 1989